You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR LIPIDIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LIPIDIL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00458055 ↗ High-Density Lipoprotein (HDL) Treatment Study Completed McGill University Health Center N/A 2006-11-01 A low level of plasma high-density lipoprotein (HDL) cholesterol, "the good cholesterol", is the most common lipid abnormality observed in patients with a premature atherosclerotic cardiovascular disease. HDL carry excess cholesterol from peripheral tissues to the liver to be metabolized or excreted, a process known as reverse cholesterol transport. Epidemiological studies have shown an inverse correlation between plasma levels of HDL cholesterol and the risk of cardiovascular disease. An increase in plasma HDL cholesterol levels by 1 mg/dL may reduce the risk of cardiovascular disease by 2 to 3%. The standard care of treatment for a low level of HDL cholesterol is: 1) lifestyle modifications including exercise, smoking cessation, weight control, moderate alcohol intake and decreased dietary fat intake - all patients are encouraged to follow these lifestyle modifications; 2) medications which can raise HDL cholesterol. Currently used medications to treat lipid disorders can increase, in some extent, HDL cholesterol. These include niacin (vitamin B3), fibric acid derivatives (fibrates) and statins. However there is no data on the effect of these medications on severe cases of HDL deficiency. This project aims to determine whether currently available medications, used in standard medical practice for the treatment of lipoprotein disorders, can substantially increase HDL cholesterol in severe cases of HDL deficiencies.
NCT00458055 ↗ High-Density Lipoprotein (HDL) Treatment Study Completed McGill University Health Centre/Research Institute of the McGill University Health Centre N/A 2006-11-01 A low level of plasma high-density lipoprotein (HDL) cholesterol, "the good cholesterol", is the most common lipid abnormality observed in patients with a premature atherosclerotic cardiovascular disease. HDL carry excess cholesterol from peripheral tissues to the liver to be metabolized or excreted, a process known as reverse cholesterol transport. Epidemiological studies have shown an inverse correlation between plasma levels of HDL cholesterol and the risk of cardiovascular disease. An increase in plasma HDL cholesterol levels by 1 mg/dL may reduce the risk of cardiovascular disease by 2 to 3%. The standard care of treatment for a low level of HDL cholesterol is: 1) lifestyle modifications including exercise, smoking cessation, weight control, moderate alcohol intake and decreased dietary fat intake - all patients are encouraged to follow these lifestyle modifications; 2) medications which can raise HDL cholesterol. Currently used medications to treat lipid disorders can increase, in some extent, HDL cholesterol. These include niacin (vitamin B3), fibric acid derivatives (fibrates) and statins. However there is no data on the effect of these medications on severe cases of HDL deficiency. This project aims to determine whether currently available medications, used in standard medical practice for the treatment of lipoprotein disorders, can substantially increase HDL cholesterol in severe cases of HDL deficiencies.
NCT00809068 ↗ High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone Completed Keogh Institute for Medical Research Phase 4 2005-08-01 Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%. This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone.
NCT01353404 ↗ Relative Bioavailability Study of LipidilĀ® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) Completed Samyang Biopharmaceuticals Corporation Phase 1 2011-06-01 The purpose of this study is to evaluate the bioequivalence of LipidilĀ® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LIPIDIL

Condition Name

Condition Name for LIPIDIL
Intervention Trials
Coronary Arteriosclerosis 1
Dyslipidemia 1
Genetic Diseases, Inborn 1
HDL Cholesterol 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LIPIDIL
Intervention Trials
Dyslipidemias 1
Hyperlipidemias 1
Myocardial Ischemia 1
Hypoalphalipoproteinemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LIPIDIL

Trials by Country

Trials by Country for LIPIDIL
Location Trials
Korea, Republic of 2
Canada 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LIPIDIL

Clinical Trial Phase

Clinical Trial Phase for LIPIDIL
Clinical Trial Phase Trials
Phase 4 1
Phase 1 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LIPIDIL
Clinical Trial Phase Trials
Completed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LIPIDIL

Sponsor Name

Sponsor Name for LIPIDIL
Sponsor Trials
McGill University Health Centre/Research Institute of the McGill University Health Centre 1
Keogh Institute for Medical Research 1
Samyang Biopharmaceuticals Corporation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LIPIDIL
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.